Comparing two stomach protectors after stem cell transplant
Treatments studied
Part of Infections clinical trials.
This study compares two medications, GMPA and PPI, that protect the stomach during a stem cell transplant. It aims to see which one is better at preventing stomach problems and reducing the risk of a complication called graft-versus-host disease (aGVHD), where donor cells attack the patient's body.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 12 and 70 years old.
- You are having your first stem cell transplant from a half-matched donor (haploidentical) to treat a blood cancer.
- You have received or will receive a standard high-dose chemotherapy conditioning regimen before the transplant.
- Your general health status is good enough (ECOG score of 2 or less) before the transplant.
- You have given written consent to participate.
- You are not currently taking certain strong stomach acid reducers (PPIs) for conditions like severe reflux or ulcers, and are not on long-term blood thinners.
- You do not have an active H. pylori infection, active gut infection, or C. diff infection.
- You have not used strong antibiotics in the last 7 days or probiotics in the last 14 days.
- You are able to provide saliva and stool samples for the study.
- You are not pregnant or breastfeeding, and do not have severe psychiatric or neurological conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a lower dose of a common drug (cyclophosphamide) after transplant can prevent graft-versus-host disease (a complication where donor cells attack your body) just as well as the standard dose. It also uses another medicine (anti-thymocyte globulin) after the transplant to help protect you.
This trial tests a combination of medications given before and after a stem cell transplant from a family member to prevent graft-versus-host disease (GVHD)—a condition where the new cells attack your body. The study includes a newer drug called ivarmacitinib that may help reduce this serious side effect.
This trial tests whether taking probiotics made from your own and your donor's bacteria can help prevent or reduce gut problems (like diarrhea) after a stem cell transplant. It may help your intestines recover and feel better.
This early-phase study tests a prebiotic (galacto-oligosaccharide) to see if it can lower or prevent gut inflammation caused by acute graft-versus-host disease (acute GVHD) after a stem cell transplant. If you’re scheduled for an allogeneic transplant, participating may help researchers find safer ways to protect your gut.
This Phase 2 study tests an oral “fecal microbiotherapy” treatment given before and around an allogeneic (donor) stem-cell transplant to help prevent transplant-related complications. It may help by improving gut and immune function during the high-risk transplant period.
This trial tests if giving the antifungal drug posaconazole as a tablet can prevent serious fungal infections in people who have had a stem cell transplant and develop gut graft-versus-host disease (GVHD), which is a complication where donor cells attack the digestive tract. It may help protect patients who need strong immune-suppressing treatment for GVHD.
Hear when a new aGVHD trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.